// App-Quantinova.ai

: Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings

Researchers

Presenter

  • Lindsey E. Roeker

Principal Investigators

  • Toby A. Eyre

  • John N. Allan

  • Stephen J. Schuster

  • Chadi Nabhan

  • Brian T. Hill

  • Nirav N Shah

  • Frederick Lansigan

  • Maryam Yazdy

  • Nicole Lamanna

  • Bruce Cheson

  • Arun K Singavi

  • Catherine C. Coombs

  • Paul Barr

  • Alan P Skarbnik

  • Mazyar Shadman

  • Hande H. Tuncer

  • Chaitra S. Ujjani

  • Allison M. Winter

  • Joanna Rhodes

  • Colleen Dorsey

  • Hannah Morse

  • John M. Pagel

  • Annalynn M Williams

  • Ryan Jacobs

  • Andre Goy

  • Sivraj Muralikrishnan

  • Laurie Pearson

  • Andrea Sitlinger

  • Neil Bailey

  • Anna Schuh

  • Danielle M. Brander

  • Amy A Kirkwood

  • Anthony R Mato

Medical Centers

  • Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom

  • Oxford University NHS Foundation Trust, Oxford, United Kingdom

  • Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

  • Cardinal Health Specialty Solutions, Deerfield, IL

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

  • Dartmouth Hitchcock Medical Center, Lebanon, NH

  • Department of Surgery, Georgetown University Hospital and Lombardi Comprehensive Cancer Center, Washington, DC

  • Hematology/Oncology Division, Columbia University Medical Center, New York, NY

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • University of Rochester, Rochester, NY

  • John Theurer Cancer Center, Myeloma and Lymphoma Divisions, Hackensack University Medical Center, Closter, NJ

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Tufts Medical Center, Boston, MA

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute,Seattle,Estados Unidos

  • University of Rochester Medcal Center, Rochester, NY

  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC

  • The John Theurer Cancer Center at Hackensack Meridian Health,Hackensack,United States

  • Department of Surgery, Duke University Medical Center, Durham, NC

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Duke University Medical Center, Durham, NC

  • Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Tumor lysis syndrome

Biomarkers

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved